JournalArta
Monday, November 16, 2026 · JakartaS&P 7,423.97 ▼1.82%USD/IDR 18,263 ▲0.19%
JournalArta
Global Edition
beyond headlines
Advertisement

ResMed Share Price Rises 0.69%: Up 2.7% in Five Sessions

Technical analysis of ResMed stock on November 16, 2026: price 35.20 AUD, trend uptrend, RSI 60.2, support 33.32, resistance 35.91.

By Elena Vance
November 16, 20263 min read
ResMed Share Price Rises 0.69%: Up 2.7% in Five Sessions
Logo ResMed — JournalArta illustration

ResMed rose 0.69% to A$35.20 on Monday, November 16, 2026, extending gains over five sessions to 2.71%. The technical picture is constructive, but momentum has softened and trading volume was thin. That makes the advance worth watching, rather than unambiguous.

Why ResMed is in focus today

    Selected automatically from 6 ASX (Australia) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

    Trend & Price Action

    The share price is above both its 20-day simple moving average (SMA), at A$34.68, and its 50-day average, at A$33.07. The 20-day average is rising 0.50% over five days, while the 20-day average remains above the 50-day average. Together, those readings support the stated uptrend; no new moving-average crossover formed in the latest session.

    Advertisement

    Price is 73% of the way through its 20-day range, between support at A$33.32 and resistance at A$35.91. It is also below the three-month high of A$37.67, after trading as low as A$30.23 during that period. The position near resistance means further gains would need to clear a nearby hurdle before the broader three-month high comes into view.

    As shown in the chart, the price sits above its moving averages and within the Bollinger bands, with resistance close overhead.

    Price action chart of ResMed
    3-month price action chart of ResMed: price, SMA20/50, Bollinger, support & resistance.

    Oscillators & Momentum

    RSI is neutral at 60.2, and the Stochastic readings are also neutral, with %K at 51.9 and %D at 45.7. These indicators do not show an overbought or oversold extreme. The MACD, however, is weaker: its value of 0.368 is below the 0.417 signal line, leaving a negative histogram of -0.049. That suggests upward price structure has not yet translated into strengthening short-term momentum.

    Advertisement

    The mix matters: neutral oscillators leave room for movement either way, while the negative MACD cautions that the latest rise lacks full momentum confirmation. As shown in the chart, the RSI and Stochastic are neutral while MACD remains below its signal line.

    Momentum chart of ResMed
    Momentum chart of ResMed: RSI(14), MACD, Stochastic.

    Volatility, Volume & Levels

    The Bollinger bands are at A$33.16 on the lower side and A$36.21 on the upper side, with price at 67% of the band range. Their 8.8% width is normal, not a squeeze or a sharp expansion. The average true range (ATR) is A$0.94, or 2.7% of the share price, indicating moderate daily volatility rather than unusually wide swings.

    Advertisement

    Volume was 1,003,195 shares, about half the 20-session average of 2,013,804, which marks the latest activity as thin. Rising on-balance volume (OBV), a measure that tracks whether volume tends to accompany gains or losses, offers a counterpoint: participation has been building over time even though this session was quiet.

    A move through A$35.91 resistance would clear the stated 20-day ceiling; failure to hold above the A$34.68 20-day average would weaken the near-term trend. The A$33.32 support and A$33.16 lower Bollinger band mark nearby downside reference points, while the three-month high at A$37.67 is a broader chart level.

    Technical Verdict: BUY

    The technical verdict is BUY, in line with JournalArta Research’s score of +84. The strongest supports are the price above its 50-day average and an uptrend confirmed by rising OBV; the 20-day average is also above the 50-day average. The main caution is the negative MACD histogram, alongside thin latest-session volume. The verdict is invalidated if price falls below A$33.13.

    Advertisement
    • Ideal entry range: A$34.50–A$35.20
    • Exit targets: A$38.30 (Target 1) and A$41.41 (Target 2)
    • Stop-loss protection: A$33.13
    • Validity: Through December 14, 2026

    In plain English, the chart leans upward, but the momentum and trading activity still call for caution.

    Summary Data ResMed

    Last price35.20 AUD
    Change 1 day / 5 days / 1 month0.69% / 2.71% / 3.32%
    Trend / MA-crossuptrend / none
    SMA20 / SMA5034.68 / 33.07
    RSI (14) / Stochastic %K60.2 / 51.9
    Bollinger %B / ATR67% / 0.94
    Support / Resistance 20 days33.32 / 35.91
    Data as of16 November 2026 12:10 WIB
    JournalArta research verdict (score)Buy (+84)
    Entry zone34.50 – 35.20
    Target 1 / 238.30 / 41.41
    Stop loss33.13
    Reward/risk1.5 / 3.0
    Advertisement

    Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

    Advertisement
    Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
    Advertisement
    Most Read
    1. 1Micron Stock Falls 28% as $35.16 Billion Buyback Nears
    2. 2I’m A Celebrity 2026 Line-Up: Rooney Leads 11 Stars Into Jungle
    3. 3Taylor Swift and the Falcons Game Today: Chiefs in Atlanta
    4. 4Actor Says David Walliams Sexually Humiliated Him on Stage
    5. 5AI Inference Pricing: AWS, Azure and Google Cloud Costs
    Advertisement
    Don't Miss

    Latest News

    All stories →
    1. Sport · FootballPhilippe Diallo Wins UEFA Backing to Challenge InfantinoNov 16
    2. BusinessUniCredit Wins EU Approval for €45 Billion Commerzbank BidNov 16
    3. World · United StatesKen Urker’s Death Ruled Accidental Drug Toxicity, Coroner SaysNov 16
    4. Business · CompaniesBlack Rifle Coffee to Close at Least 12 Stores by Early 2027Nov 16
    5. Advertisement
    6. Lifestyle · Food & HealthBatoul Chreifi Finds Lymphoma Behind Gym-Blamed Shoulder PainNov 16
    7. Lifestyle · Food & HealthBeing Sceptical of Medical Studies Can Help Protect HealthNov 16
    8. WorldBahrain Sentences 64 Shiite Clerics to Life in PrisonNov 16
    9. World · AustraliaQueensland hail reaches 10cm as storms bring flood riskNov 16